Donor cell leukemia is a rare complication after allogeneic hematopoietic stem cell transplantation. A twelve month old boy underwent unrelated donor umbilical cord blood transplant (UCBT) for refractory Langerhan's cell histiocytosis. Forty months following transplant he developed acute myeloid leukemia. Cytogenetic and molecular analysis confirmed donor cell origin. The Cord Blood Bank (CBB) contacted the donor's family and established that the child, now seven years old, was healthy. This represents the first reported case of donor cell leukemia following UCBT. This case illustrates that donor cell leukemia is a rare but real event after UCBT as with other stem cell sources and highlights the need for CBBs to maintain linkage data between donors and recipients.
Introduction
Donor cell leukemia (DCL) is a rare complication following allogeneic hematopoietic stem cell transplantation, with approximately 25 cases previously reported. [1] [2] [3] [4] [5] [6] [7] Umbilical cord blood has emerged as an alternative source of hematopoietic stem cells over the past decade with more than 6000 umbilical cord blood transplants (UCBTs) performed worldwide. 8 We report the first case of DCL following UCBT.
The etiology of DCL is unclear and the reported literature doesn't suggest a common mechanism. Mechanisms proposed include occult leukemia in the donor, impaired immune surveillance, chemotherapy or radiation induced stromal abnormalities, inherent stromal abnormalities, transformation of donor cells by antigenic stimulation through host tissue and fusion of donor cells with residual leukemic cells resulting in oncogene transfection. 1 The possibility of occult leukemia in the donor raises the question as to whether notification and investigation are warranted.
Study Design
This is a single case report with retrospective analysis of clinical and laboratory data.
The Institutional Review Board of the University of Minnesota reviewed the protocols and informed consent documents relevant to the individual patient.
For personal use only. on After lymph node biopsy demonstrated histiocytic infiltration and immunohistochemical staining was positive for CD1a, a diagnosis of Langerhan's cell histiocytosis was made.
Cytogenetic analyses of both the bone marrow and lymph node specimens revealed normal 46,XY male karyotypes with no evidence of a clonal chromosomal abnormality.
There was no response to therapy with steroids, vinblastine and etoposide or salvage therapy with 2-chlorodeoxyadenosine. Five months after presentation, a two antigen mismatched, male donor UCBT was performed with a preparative regimen of busulfan, cyclophosphamide, etoposide and ATG. GVHD prophylaxis consisted of cyclosporine and short course steroids. 9 The total nucleated cell dose was 5.6x10 7 For personal use only. on . by guest www.bloodjournal.org From
Methods
Cytogenetics: Cytogenetic evaluation involved G-banded analysis of twenty metaphase cells from unstimulated, cultured (24 hour) bone marrow aspirates. All numerical and structural chromosomal abnormalities were characterized according to the ISCN, 1995. 10 Molecular Diagnostics: Genomic DNA was extracted from the bone marrow sample and amplified by PCR using a series of fluorescently labeled oligonucleotide primers specific for highly polymorphic genetic markers (VNTR) according to standard methods. 11 Pretransplant samples from the donor and recipient were previously analyzed for informative markers. The resulting products were analyzed on a Model 3100/Genescan system, (Applied Biosytems) from which the pre and post transplant specimens were compared.
Results
Nineteen of 20 metaphase cells examined comprised a clone characterized by a derivative chromosome 7, with its distal long arm at band 7q21.1 replaced by an extra copy of most of the long arm of a chromosome 1. Thus, this abnormality, designated as, , 46,XY,der(7)t(1;7)(q21.1;q22), results in monosomy for the region extending from 7q21.1 to the 7q telomere, and trisomy for the 1q region extending from 1q22 to the 1q telomere ( Figure 2 ). Cytogenetic analysis of the patient's karyotype pre and post UCBT demonstrated an informative G band polymorphism on the short arm of chromosome 22.
The polymorphism of chromosome 22 showed the post-transplant cells to be of donor 18-20 Several of these children were older than 10 years at the time of leukemia diagnosis.
This protracted postnatal latency would suggest that additional events or exposures are required for the development of leukemia. A follow up study which demonstrated that the TEL-AML1 translocation was detectable at frequencies consistent with clonal expansion in 6 of 567 cord blood samples screened is consistent with this hypothesis 21 but also suggests that pre-leukemic cells may be infused more commonly than expected during UCBT. It has already been suggested that these data argue against the use of stored cord blood in an autologous setting for leukemia patients. 
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This first report of DCL after UCBT demonstrates that DCL is a risk following allogeneic transplantation irrespective of the graft source. Given the lack of evidence of occult leukemia in the donor as a cause of this rare complication and the absence of prophylactic treatment, we would argue that donor notification and investigation is not warranted.
However, this case serves as a reminder of the ethical dilemmas that will undoubtedly be faced as the number of UCBTs performed increases and the need for standardization of regulations governing CBBs. 
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